Correction: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
نویسندگان
چکیده
After the publication of this work [1], we noticed that we had incorrectly used the term ‘OGX-011’. All instances of OGX-011 in the manuscript should be changed to ‘ASO-CLU’, apart from the last paragraph in the Introduction section which should remain as published. We also noticed in the first sentence of the second paragraph of the Materials and methods section we mistakenly stated that OGX-011 (ASO-CLU) was purchased from OncoGenex Technologies. As ASO-CLU is currently in the clinical testing phase, it is not available for sale from OncoGenex Technologies. The corrected sentence should read: ASO-CLU was acquired from OncoGenex Technologies. We apologise to the readers and OncoGenex Technologies for this oversight and any negative effects that may have resulted from it.
منابع مشابه
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
OBJECTIVES To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer cells by inhibition of clusterin-dependent pERK1/2 activation. METHODS Clusterin was silenced by serial concentration of OGX-011 transfection in pancreatic cancer MIAPaCa-2...
متن کاملpERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression
BACKGROUND Our previous study has demonstrated that knockdown of activated ERK1/2(pERK1/2) sensitizes pancreatic cancer cells to chemotherapeutic drug gemcitabine (Gem) treatment. However, the details of this survival mechanism remain undefined. It has also shown that Bcl-2 confers resistance and Bax sensitizes to gemcitabine-induced apoptosis in pancreatic cancer cells. Furthermore, the extrac...
متن کاملKnockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy
The treatment of prostate cancer patients usually starts with androgen ablation and followed by chemotherapy; however, in some cases the tumor develops resistant phenotype. Combination therapy is currently regarded as a cornerstone in cancer therapy to overcome the drug resistance. Herein, we investigated the combinatory effect of Docetaxel and Trastuzumab with a novel nanomedicine, BCc1. Also,...
متن کاملClusterin silencing sensitizes pancreatic cancer MIA-PaCa-2 cells to gmcitabine via regulation of NF-kB/Bcl-2 signaling.
Clusterin (CLU) is known as a multifunctional protein involved in a variety of physiological processes including lipid transport, epithelial cell differentiation, tumorigenesis, and apoptosis. Our recent study has demonstrated that knockdown of clusterin sensitizes pancreatic cancer cell lines to gmcitabine treatment. However the details of this survival mechanism remain undefined. Of the vario...
متن کاملSecreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells
BACKGROUND Several studies have shown that secreted clusterin (sCLU) up-regulation in multi-drug resistant osteosarcoma (OS) cells relates to enhanced drug resistance. Furthermore, sCLU silencing directed against sCLU induces significant reduction of cellular growth and sensitizes OS cells to chemotherapy. However, the molecular mechanisms underlying the effect of sCLU on OS cells are not known...
متن کامل